Literature DB >> 16844034

Ornithine alpha-ketoglutarate counteracts thymus involution and glutamine depletion in endotoxemic rats.

E Lasnier1, C Coudray-Lucas, J Le Boucher, A Jardel, L Cynober.   

Abstract

This work studied the action of ornithine a-ketoglutarate (OKG) supplementation in an experimental model of endotoxemia in the rat. Male Wistar rats were injected intraperitoneally with lipopolysaccharide (LPS) from Escherichia coli (0127:B8). They were fasted for 24 h, then refed for 48 h with an enteral diet supplemented with either OKG (66 mg N x kg(-1) x d(-1)) or glycine, isonitrogenous to the OKG group. A control (sham) group was also studied. LPS treatment induced a decrease in thymus and muscle weights compared to controls, and a decrease in glutamine and arginine concentrations in the anterior tibialis muscle. Supplementation with OKG restored thymus weight and muscle arginine level and increased muscle glutamine concentration, when compared to controls. We conclude that OKG counteracts the thymic involution that occurs with endotoxemia, and restores the muscular content of glutamine and arginine, both of which are involved in the regulation of immune function.

Entities:  

Year:  1996        PMID: 16844034     DOI: 10.1016/s0261-5614(96)80241-x

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  3 in total

1.  The equivocal metabolic response to endotoxaemia in type 2 diabetic and obese ZDF rats.

Authors:  L Belabed; G Senon; M-C Blanc; A Paillard; L Cynober; S Darquy
Journal:  Diabetologia       Date:  2006-04-19       Impact factor: 10.122

2.  Effect of ornithine alpha-ketoglutarate on glutamine pools in burn injury: evidence of component interaction.

Authors:  L Cynober; E Lasnier; J Le Boucher; A Jardel; C Coudray-Lucas
Journal:  Intensive Care Med       Date:  2007-01-18       Impact factor: 17.440

Review 3.  Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: From pathogenesis to therapy prospects.

Authors:  Xiaojin Feng; Xue Li; Na Liu; Ningning Hou; Xiaodong Sun; Yongping Liu
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.